Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SGS 742

Next Previous
X
Search
Drug Profile

SGS 742

Alternative Names: CGP-36742; DVD-742; Lu-AE58479; SGS-742

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Lundbeck A/S; Novartis
  • Class Antidementias; Antiepileptic drugs; Nootropics; Organophosphorus compounds
  • Mechanism of Action GABA B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder; Epilepsy; Mild cognitive impairment

Most Recent Events

  • 13 Dec 2005 Data presented at the 35th Annual Meeting of the Society of Neuroscience (SfN-2005) have been added to the Alzheimer's Disease pharmacodynamics section
  • 22 Mar 2005 Phase-II clinical trials in Attention-deficit hyperactivity disorder in USA (PO)
  • 10 May 2004 Data presented at the 56th Annual Meeting of the American Academy of Neurology (AAN-2004) have been added to the adverse events section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top